Adlarity (Donepezil HCl) Patent Expiration, LOE Window & CMS Spending

Adlarity (Donepezil HCl) by Corium/Prasco L: FDA Orange Book core substance LOE 2036-12-30 (last listed 2038-08-11), 22 AB generics, $2.6M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorCorium/Prasco L
FDA Application & PathwayN212304 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2036-12-30
Last Listed Patent or Exclusivity Date2038-08-11
Orange Book Patents (*PED Extensions)11 patents (0 *PED)
Active AB-Rated Generic Competitors22
2024 CMS Total Public Spend$2.6M
2024 Medicare Part D Spend$2.5M
2024 Medicaid Spend$125K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel